Cardiac differentiation of human pluripotent stem cells in scalable suspension culture

Nature Protocols

Volumn 10, Issue 9, 2015, Pages 1345-1361

  Kempf, Henning ^a   Kropp, Christina ^a   Olmer, Ruth ^a,b   Martin, Ulrich ^a,b   Zweigerdt, Robert ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b German Center for Lung Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; PROTEIN TRA 1 60; STAGE SPECIFIC EMBRYO ANTIGEN 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOREACTOR; CELL AGGREGATION; CELL DIFFERENTIATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; HEART MUSCLE CELL; HUMAN; HUMAN CELL; MONOLAYER CULTURE; MOUSE; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SCALE UP; STEM CELL EXPANSION; SUSPENSION CELL CULTURE; WNT SIGNALING PATHWAY; CARDIAC MUSCLE CELL; CELL CULTURE TECHNIQUE; CYTOLOGY; PHYSIOLOGY;

CELL CULTURE TECHNIQUES; HUMANS; MYOCYTES, CARDIAC; PLURIPOTENT STEM CELLS;

EID: 84940565573     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2015.089     Document Type: Article

References (47)

1. Schwartz, S.D. et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 385, 509-516 (2015).
2. Zweigerdt, R. Large scale production of stem cells and their derivatives. Adv. Biochem. Eng. Biotechnol. 114, 201-235 (2009).
3. Cantz, T., Sharma, A.D. & Ott, M. Concise review: cell therapies for hereditary metabolic liver diseases-concepts, clinical results, and future developments. Stem Cells 33, 1055-1062 (2015).
4. ViaCyte. A Safety, Tolerability, and Effcacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus. https://clinicaltrials.gov/ ct2/show/NCT02239354 (23/03/2015).
5. Chong, J.J., et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510, 273-277 (2014).
6. Lian, X. et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc. Natl. Acad. Sci. USA 109, E1848-E1857 (2012).
7. Lian, X. et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defned conditions. Nat. Protoc. 8, 162-175 (2013).
8. Burridge, P.W. et al. Chemically defned generation of human cardiomyocytes. Nat. Methods 11, 855-860 (2014).
9. Burridge, P.W., Keller, G., Gold, J.D. & Wu, J.C. Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 10, 16-28 (2012).
10. Mummery, C.L. et al. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ. Res. 111, 344-358 (2012).
11. Olmer, R. et al. Long term expansion of undifferentiated human iPS and ES cells in suspension culture using a defned medium. Stem Cell Res. 5, 51-64 (2010).
12. Singh, H., Mok, P., Balakrishnan, T., Rahmat, S.N. & Zweigerdt, R. Up-scaling single cell-inoculated suspension culture of human embryonic stem cells. Stem Cell Res. 4, 165-179 (2010).
13. Zweigerdt, R., Olmer, R., Singh, H., Haverich, A. & Martin, U. Scalable expansion of human pluripotent stem cells in suspension culture. Nat. Protoc. 6, 689-700 (2011).
14. Amit, M. et al. Dynamic suspension culture for scalable expansion of undifferentiated human pluripotent stem cells. Nat. Protoc. 6, 572-579 (2011).
15. Konze, S.A. et al. Cleavage of E-cadherin and β-catenin by calpain affects Wnt signaling and spheroid formation in suspension cultures of human pluripotent stem cells. Mol. Cell. Proteomics 13, 990-1007 (2014).
16. Wang, Y. et al. Scalable expansion of human induced pluripotent stem cells in the defned xeno-free E8 medium under adherent and suspension culture conditions. Stem Cell Res. 11, 1103-1116 (2013).
17. Beers, J. et al. Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defned culture conditions. Nat. Protoc. 7, 2029-2040 (2012).
18. Serra, M. et al. Improving expansion of pluripotent human embryonic stem cells in perfused bioreactors through oxygen control. J. Biotechnol. 148, 208-215 (2010).
19. Ting, S., Chen, A., Reuveny, S. & Oh, S. An intermittent rocking platform for integrated expansion and differentiation of human pluripotent stem cells to cardiomyocytes in suspended microcarrier cultures. Stem Cell Res. 13, 202-213 (2014).
20. Chu, L. & Robinson, D.K. Industrial choices for protein production by large-scale cell culture. Curr. Opin. Biotechnol. 12, 180-187 (2001).
21. Tolner, B., Smith, L., Begent, R.H. & Chester, K.A. Production of recombinant protein in Pichia pastoris by fermentation. Nat. Protoc. 1, 1006-1021 (2006).
22. Olmer, R. et al. Suspension culture of human pluripotent stem cells in controlled, stirred bioreactors. Tissue Eng. Part C Methods 18, 772-784 (2012).
23. Schroeder, M. et al. Differentiation and lineage selection of mouse embryonic stem cells in a stirred bench scale bioreactor with automated process control. Biotechnol. Bioeng. 92, 920-933 (2005).
24. Niebruegge, S. et al. Cardiomyocyte production in mass suspension culture: embryonic stem cells as a source for great amounts of functional cardiomyocytes. Tissue Eng. Part A 14, 1591-1601 (2008).
25. Niebruegge, S. et al. Generation of human embryonic stem cell-derived mesoderm and cardiac cells using size-specifed aggregates in an oxygen-controlled bioreactor. Biotechnol. Bioeng. 102, 493-507 (2009).
26. Chen, V.C. et al. Scalable GMP compliant suspension culture system for human ES cells. Stem cell Res. 8, 388-402 (2012).
27. Lecina, M., Ting, S., Choo, A., Reuveny, S. & Oh, S. Scalable platform for human embryonic stem cell differentiation to cardiomyocytes in suspended microcarrier cultures. Tissue Eng. Part C Methods 16, 1609-1619 (2010).
28. Xu, X.Q., Soo, S.Y., Sun, W. & Zweigerdt, R. Global expression profle of highly enriched cardiomyocytes derived from human embryonic stem cells. Stem Cells 27, 2163-2174 (2009).
29. Hemmi, N. et al. A massive suspension culture system with metabolic purifcation for human pluripotent stem cell-derived cardiomyocytes. Stem Cells Transl. Med. 3, 1473-1483 (2014).
30. Fuerstenau-Sharp, M. et al. Generation of highly purifed human cardiomyocytes from peripheral blood mononuclear cell-derived induced pluripotent stem cells. PloS ONE 10, e0126596 (2015).
31. Kempf, H. et al. Controlling expansion and cardiomyogenic differentiation of human pluripotent stem cells in scalable suspension culture. Stem Cell Rep. 3, 1132-1146 (2014).
32. Elliott, D.A. et al. NKX2-5(eGFP/w) hESCs for isolation of human cardiac progenitors and cardiomyocytes. Nat. Methods 8, 1037-1040 (2011).
33. eGFP/w hESCs enable studying early human cardiac differentiation. Stem Cells 33, 56-67 (2015).
34. Wang, G. et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat. Med. 20, 616-623 (2014).
35. Zweigerdt, R., Gruh, I. & Martin, U. Your heart on a chip: iPSC-based modeling of Barth-syndrome-associated cardiomyopathy. Cell Stem Cell 15, 9-11 (2014).
36. Kensah, G. et al. Murine and human pluripotent stem cell-derived cardiac bodies form contractile myocardial tissue in vitro. Eur. Heart J. 34, 1134-1146 (2013).
37. Anderson, M.E., Goldhaber, J., Houser, S.R., Puceat, M. & Sussman, M.A. Embryonic stem cell-derived cardiac myocytes are not ready for human trials. Circ. Res. 115, 335-338 (2014).
38. Fluri, D.A. et al. Derivation, expansion and differentiation of induced pluripotent stem cells in continuous suspension cultures. Nat. Methods 9, 509-516 (2012).
39. Huang, S.X. et al. The in vitro generation of lung and airway progenitor cells from human pluripotent stem cells. Nat. Protoc. 10, 413-425 (2015).
40. Lachmann, N. et al. Large-scale hematopoietic differentiation of human induced pluripotent stem cells provides granulocytes or macrophages for cell replacement therapies. Stem Cell Rep. 4, 282-296 (2015).
41. Hannan, N.R.F., Segeritz, C.P., Touboul, T. & Vallier, L. Production of hepatocyte-like cells from human pluripotent stem cells. Nat. Protoc. 8, 430-437 (2013).
42. Sgodda, M. et al. Improved hepatic differentiation strategies for human induced pluripotent stem cells. Curr. Mol. Med. 13, 842-855 (2013).
43. Siller, R., Greenhough, S., Naumovska, E. & Sullivan, G.J. Small-molecule-driven hepatocyte differentiation of human pluripotent stem cells. Stem Cell Rep. 4, 939-952 (2015).
44. Pagliuca, F.W. et al. Generation of functional human pancreatic beta cells in vitro. Cell 159, 428-439 (2014).
45. Katsirntaki, K. et al. Bronchoalveolar sublineage specifcation of pluripotent stem cells: effect of dexamethasone plus cAMP-elevating agents and keratinocyte growth factor. Tissue Eng. Part A 21, 669-682 (2015).
46. Hartung, S. et al. Directing cardiomyogenic differentiation of human pluripotent stem cells by plasmid-based transient overexpression of cardiac transcription factors. Stem Cells Dev. 22, 1112-1125 (2013).
47. Haase, A. et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 5, 434-441 (2009).